US Patent No. 6,361,770:

“Method of Enhancing Expression of MHC Class I Molecules Bearing Endogenous Peptides”

The patent, in combination with a pending U.S. patent application derived from it, provides comprehensive protection for the use of TAP-1 (transporters associated with antigen processing) as an immunotherapy against all cancers.  The patent was issued on March 26, 2002 by the United States Patent and Trademark Office to the University of British Columbia. It provides comprehensive protection and coverage to both in vivo and ex vivo applications of TAP-1 as a therapy against all cancers with a variety of delivery mechanisms.

Corresponding patents have been granted in France, Germany, United Kingdom and Switzerland, and there is a corresponding application pending in Japan.

US Patent No. 5,792,604

Method of Identifying MHC Class I Restricted Antigens Endogenously Processed by a Secretory Pathway

This patent covers the Immunomodulating Peptide Transfer Assay (IPTA), which can identify compounds capable of modulating the immune system.  The patent was issued on August 11, 1998 by the United States Patent and Trademark Office to the University of British Columbia. It is a patent for the use of bioengineered cell lines to measure the output of the MHC class I restricted antigen presentation pathway as a way to screen for immunomodulating drugs.

Patent protection for this patent is also held in Canada, Japan and Europe.

Future Patented Technologies

Additional patent applications have been filed with respect to TapImmune’s technologies.  TapImmune intends to continue to file patent applications for any novel aspects of our technology to protect the intellectual property of the company.